175 related articles for article (PubMed ID: 17488660)
1. A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy.
Dmoszynska A; Kloczko J; Rokicka M; Hellmann A; Spicka I; Eid JE
Haematologica; 2007 Apr; 92(4):493-501. PubMed ID: 17488660
[TBL] [Abstract][Full Text] [Related]
2. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
3. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.
Locatelli F; Villa G; de Francisco AL; Albertazzi A; Adrogue HJ; Dougherty FC; Beyer U;
Curr Med Res Opin; 2007 May; 23(5):969-79. PubMed ID: 17519064
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial].
Chen N; Qian JQ; Mei CL; Zhang AH; Xing CY; Wang L; Liu WH; Wang M; Chen JH; Liu BC; Hou FF; Chen XM; Zuo L; Shi W; Yu LB; Zhang Y
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):502-7. PubMed ID: 22943819
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
6. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
7. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
8. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy.
Osterborg A; Steegmann JL; Hellmann A; Couban S; Mayer J; Eid JE
Br J Haematol; 2007 Mar; 136(5):736-44. PubMed ID: 17313376
[TBL] [Abstract][Full Text] [Related]
10. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
Hirsh V; Glaspy J; Mainwaring P; Manegold C; Ramlau R; Eid JE
Trials; 2007 Mar; 8():8. PubMed ID: 17341293
[TBL] [Abstract][Full Text] [Related]
14. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
15. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
16. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
Cazzola M; Messinger D; Battistel V; Bron D; Cimino R; Enller-Ziegler L; Essers U; Greil R; Grossi A; Jäger G; LeMevel A; Najman A; Silingardi V; Spriano M; van Hoof A; Ehmer B
Blood; 1995 Dec; 86(12):4446-53. PubMed ID: 8541533
[TBL] [Abstract][Full Text] [Related]
18. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
19. Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial.
Koch M; Henrich D; Faust J; Nawka J; Rath T; Wanner C
Clin Nephrol; 2012 Sep; 78(3):189-97. PubMed ID: 22874107
[TBL] [Abstract][Full Text] [Related]
20. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
